Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the prospective ARMYDA-AGEs study)

Cristiano Spadaccio, Giuseppe Patti, Federico De Marco, Raffaella Coccia, Fabio Di Domenico, Francesco Pollari, Roberta Zanzonico, Matteo Pettinari, Mario Lusini, Germano Di Sciascio, Elvio Covino, Massimo Chello

Research output: Contribution to journalArticlepeer-review

Abstract

Diabetes mellitus (DM) remains the main predictor of restenosis rates and cardiovascular events following successful percutaneous coronary intervention (PCI) despite the use of drug-eluting stents (DES). HbA1c 17 μM was found to be an independent predictor of ISR at 6 months and stent lumen loss. AGEs failed to predict occurrence of secondary endpoints. In conclusion, elevated AGE levels predict occurrence of in-stent restenosis after DES implantation in patients with DM on optimized glycemic control and might represent a dosable marker of adverse outcome after PCI.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalThe American Journal of Cardiology
Volume112
Issue number1
DOIs
Publication statusPublished - Jul 1 2013

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the prospective ARMYDA-AGEs study)'. Together they form a unique fingerprint.

Cite this